{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:46:44Z","timestamp":1793375204973,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jchf.2024.10.016","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T15:13:56Z","timestamp":1734534836000},"page":"200-212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Endpoint Selection in Randomized Clinical Trials for Hypertrophic Cardiomyopathy"],"prefix":"10.1016","volume":"13","author":[{"given":"Alberto","family":"Aimo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Todiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9042-340X","authenticated-orcid":false,"given":"Andrea","family":"Barison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Panichella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Fiuzat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9039-6023","authenticated-orcid":false,"given":"Cecilia","family":"Linde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal K.","family":"Lakdawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Maron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2024.10.016_bib1","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2024.10.016_bib2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jacc.2008.11.069","article-title":"The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy","volume":"54","author":"Maron","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2024.10.016_bib3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.amjmed.2016.09.015","article-title":"Nonobstructive hypertrophic cardiomyopathy out of the shadows: known from the beginning but largely ignored\u2026 until now","volume":"130","author":"Maron","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.jchf.2024.10.016_bib4","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12955-021-01800-1","article-title":"Enabling patient-reported outcome measures in clinical trials, exemplified by cardiovascular trials","volume":"19","author":"Coles","year":"2021","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jchf.2024.10.016_bib5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jchf.2019.12.011","article-title":"Endpoints in heart failure drug development: history\u00a0and future","volume":"8","author":"Fiuzat","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2024.10.016_bib6","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2024.10.016_bib8","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1161\/CIRCULATIONAHA.106.670901","article-title":"Identifying heart failure patients at high risk for near-term cardiovascular events with serial health status assessments","volume":"115","author":"Kosiborod","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.10.016_bib10","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/ejhf.2923","article-title":"NYHA functional classification for decision-making in heart failure: time to reassess?","volume":"25","author":"Zimerman","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2024.10.016_bib11","first-page":"1495","article-title":"Cardiovascular outcomes by time-varying New York Heart Association class among patients with obstructive hypertrophic cardiomyopathy: a retrospective cohort study","volume":"26","author":"Wang","year":"2023","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.jchf.2024.10.016_bib12","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCHEARTFAILURE.114.002248","article-title":"Cardiopulmonary exercise testing and prognosis in hypertrophic cardiomyopathy","volume":"8","author":"Coats","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2024.10.016_bib13","first-page":"700","article-title":"Normal standards for an incremental progressive cycle ergometer test","volume":"131","author":"Jones","year":"1985","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jchf.2024.10.016_bib14","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1164\/arrd.1984.129.2P2.S49","article-title":"Predicted values for clinical exercise testing","volume":"129","author":"Hansen","year":"1984","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jchf.2024.10.016_bib15","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/cpf.12459","article-title":"Reproducibility of peak oxygen consumption and the impact of test variability on classification of individual training responses in young recreationally active adults","volume":"38","author":"Edgett","year":"2018","journal-title":"Clin Physiol Funct Imaging"},{"key":"10.1016\/j.jchf.2024.10.016_bib16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2024.10.016_bib17","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/jamacardio.2023.3030","article-title":"Effect of mavacamten on Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: the EXPLORER-CN randomized clinical trial","volume":"8","author":"Tian","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2024.10.016_bib18","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2024.10.016_bib20","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/clc.20594","article-title":"Left ventricular outflow tract gradient variability in hypertrophic cardiomyopathy","volume":"32","author":"Geske","year":"2009","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jchf.2024.10.016_bib21","first-page":"E37","article-title":"Gradient variability in hypertrophic cardiomyopathy: New insights from computer-assisted, high fidelity, rest and exercise hemodynamic analysis","volume":"94","author":"Bauch","year":"2019","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.jchf.2024.10.016_bib23","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.cardfail.2010.07.245","article-title":"Serum levels of high-sensitivity troponin T: a novel marker for cardiac remodeling in hypertrophic cardiomyopathy","volume":"16","author":"Moreno","year":"2010","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jchf.2024.10.016_bib24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.amjcard.2021.04.040","article-title":"Usefulness of high-sensitivity cardiac troponin T to predict long-term outcome in patients with hypertrophic cardiomyopathy","volume":"152","author":"Gommans","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2024.10.016_bib25","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jchf.2023.05.033","article-title":"Association between wearable device measured activity and patient-reported outcomes for heart failure","volume":"11","author":"Golbus","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2024.10.016_bib26","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1901183","article-title":"Large-scale assessment of a smartwatch to identify atrial fibrillation","volume":"381","author":"Perez","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2024.10.016_bib27","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.echo.2022.08.012","article-title":"A\u00a0novel handheld echocardiography device with continuous-wave Doppler capability: implications for the evaluation of aortic stenosis severity","volume":"35","author":"Sachpekidis","year":"2022","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jchf.2024.10.016_bib28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1109\/RBME.2019.2905730","article-title":"Point-of-care testing devices for heart failure analyzing blood and saliva samples","volume":"13","author":"Tripoliti","year":"2020","journal-title":"IEEE Rev Biomed Eng"},{"issue":"7","key":"10.1016\/j.jchf.2024.10.016_bib32","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ Res"},{"issue":"30","key":"10.1016\/j.jchf.2024.10.016_bib33","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1093\/eurheartj\/ehae421","article-title":"Genetics of hypertrophic cardiomyopathy: established and emerging implications for clinical practice","volume":"45","author":"Lopes","year":"2024","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.jchf.2024.10.016_bib34","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/15353702211072453","article-title":"Allele-specific silencing by RNAi of R92Q and R173W mutations in cardiac troponin T","volume":"247","author":"Migliore","year":"2022","journal-title":"Exp Biol Med (Maywood)"},{"issue":"1","key":"10.1016\/j.jchf.2024.10.016_bib35","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jacbts.2021.07.012","article-title":"Translation of New and Emerging Therapies for Genetic Cardiomyopathies","volume":"7","author":"Helms","year":"2021","journal-title":"JACC Basic Transl Sci"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177924008059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177924008059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T01:22:58Z","timestamp":1769908978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177924008059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2213177924008059"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2024.10.016","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endpoint Selection in Randomized Clinical Trials for Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2024.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}